TRIM2: A Potential Drug Target and Biomarker (G23321)

Target Name: TRIM2

NCBI ID: G23321

TRIM2

TRIM2: A Potential Drug Target and Biomarker

TRIM2 (Tripartite motif containing 2), also known as NEDD8, is a non-coding RNA molecule that plays a crucial role in various cellular processes. It is composed of three distinct domains: an NEDD8-like domain, a GFP-like domain, and a TBP-like domain. The NEDD8-like domain contains a conserved core motif, which is similar to the NEDD8 protein, while the GFP-like domain contains a green fluorescent protein (GFP) gene. The TBP-like domain is responsible for the trimerization of TRIM2, which is essential for its transcriptional activity.

TRIM2 is a highly conserved gene that is expressed in various tissues and organs, including brain, heart, liver, and pancreas. It has been implicated in various cellular processes, including cell adhesion, migration, and transcriptional regulation (3).TRIM2 has also been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most significant findings related to TRIM2 is its potential as a drug target. TRIM2 has been shown to play a role in various oncogenic processes, including the regulation of cell proliferation, angiogenesis, and metastasis. Several studies have shown that inhibiting TRIM2 can lead to a reduction in cancer cell proliferation and survival.

TRIM2 has also been shown to be involved in the regulation of cellular migration and adhesion. Several studies have shown that TRIM2 can interact with various adhesion molecules, including E-cadherin, N-cadherin, and vimentin. These interactions are critical for the proper functioning of cellular adhesion and migration.

In addition to its role in cell adhesion and migration, TRIM2 has also been shown to play a role in transcriptional regulation. Several studies have shown that TRIM2 can interact with various transcription factors, including NF-kappa-B, AP-1, and STAT3. These interactions are critical for the proper functioning of gene expression and have implications for various diseases, including cancer and neurodegenerative diseases.

TRIM2 has also been shown to be involved in the regulation of cellular apoptosis. Several studies have shown that TRIM2 can interact with various cellular stress response pathways, including the DNA damage response. These interactions are critical for the proper functioning of cellular apoptosis and have implications for various diseases, including neurodegenerative diseases.

In conclusion, TRIM2 is a non-coding RNA molecule that plays a crucial role in various cellular processes. Its potential as a drug target has been shown through various studies, including its involvement in cell adhesion, migration, and transcriptional regulation. Further research is needed to fully understand the implications of TRIM2 as a drug target and biomarker.

Protein Name: Tripartite Motif Containing 2

Functions: UBE2D1-dependent E3 ubiquitin-protein ligase that mediates the ubiquitination of NEFL and of phosphorylated BCL2L11. Plays a neuroprotective function. May play a role in neuronal rapid ischemic tolerance. Plays a role in antiviral immunity and limits New World arenavirus infection independently of its ubiquitin ligase activity (PubMed:24068738)

The "TRIM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets